DJIA 16,061.43 34.38 0.21%
NASDAQ 4,295.40 11.65 0.27%
S&P 500 1,856.65 3.21 0.17%
market minute promo

Biogen (NASDAQ: BIIB)

250.53 -0.24 (-0.10%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

BIIB $251.20 0.17%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $246.54
Previous Close $250.77
Daily Range $243.85 - $255.00
52-Week Range $243.85 - $480.18
Market Cap $55.8B
P/E Ratio 16.39
Dividend (Yield) $0.00 (0.0%)
Volume 1,886,864
Average Daily Volume 2,080,250
Current FY EPS $16.60

Sector

Healthcare

Industry

Drug Makers

Biogen (BIIB) Description

The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies. Website: http://www.biogenidec.com/

News & Commentary Rss Feed

The Agony of High Returns

Even with a time machine, a lot of people wouldn't want to own the best-performing stocks.

Biotech ETFs Slide as Stocks Report Mixed Q4 Results

Schoenebaum: Biotech P/Es Show 'Buying Signal' With Caveat; Amgen, Biogen, Celgene & Gilead Have Cat

Schoenebaum: Biotech P/Es Show 'Buying Signal' With Caveat; Amgen, Biogen, Celgene & Gilead Have Catalysts

Biogen Inc. Takes Aim at Johnson & Johnson

Biogen's Samsung Bioepis has Remicade in its crosshairs.

Notable Friday Option Activity: BIIB, EIGI, ALLY

Biogen (BIIB) Stock Gets ‘Market Perform’ Rating at Leerink

Leerink Is Back On Board The Biotech Train

The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Intrexon and NewLink

FBT, TECH, QGEN, BIIB: Large Outflows Detected at ETF

The Medicines Company Appoints Sarissa Capital Management Exec To Its Board Of Directors

See More BIIB News...

BIIB's Top Competitors

BIIB $250.53 (-0.10%)
Current stock: BIIB
AMGN $143.97 (0.68%)
Current stock: AMGN
GILD $87.79 (2.97%)
Current stock: GILD
$0.00 (0.00%)
Current stock: